Preliminary Program

Day 1 - October 18, 2010
at Brandeis University Hassenfeld Conference Center, 415 South Street, Waltham, MA 02454

Registration, breakfast and networking

Value Creation by Life Science Companies:  How to Deal with Concerns and Challenges Facing Health Care Providers, Payers, Policy Makers and Investors

Healthcare providers face increasing cost pressures, growing demand for quality and safety and mounting new government mandates. A distinguished group of experts will explore the challenges of providers and health plans as they determine when to adopt new technologies and how to afford them, as well as how the complex environment affects investors in companies that have already developed innovative products but are yet to cross the market acceptance chasm.

Panel Discussions

Moderators:

• Stephen Weiner, Partner, Chair of the Health Law practice, Mintz Levin
• Eyal Zimlichman, M.D., Brigham and Women’s Hospital
• Jon Kravetz, Partner, Chair of the Securities Practice, Mintz Levin

1. The Hospitals’ Dilemma: New Technologies – Pros and Cons

• David Bates, M.D., Chief of Division of General Internal Medicine, Brigham and Women’s Hospital

• Eric Halvorsen, Ph.D., Director, Technology & Innovation Technology Office, Children’s Hospital, Boston

• Leslie Selbovitz, M.D., Chief Medical Officer and Senior Vice President for Medical Affairs, Newton-Wellesley Hospital

2. Insurance Companies’ Expectations of New Technologies

• Michael Berelowitz, M.D., Senior Vice President and Head of Clinical Development and Medical Affairs, Pfizer

• Thomas Hawkins, M.D., Medical Director, Health Informatics, Blue Cross Blue Shield of Massachusetts
• Charles Petrie, Ph.D., Head, Outcomes Research Clinical Development and Medical Affairs Specialty Care, Pfizer

3. Financing Challenges for Later Stage Life Science Companies

• Fredrick Frank, Vice Chairman, Peter J. Solomon Company

• Jami Rubin, Managing Director, Global Investment Research, Goldman Sachs

• Ido Schoenberg, M.D., Chairman and Chief Executive Office, American Well Corporation

Massachusetts-Israel Life Sciences Collaborations

Companies rooted in both places have a long and often successful shared history of creating effective and profit-making products and services. Why have Massachusetts and Israel been so well-suited to collaboration, and what’s ahead? Gain insights from the leaders of the state’s economic agencies and the biopharma and medical device councils - how to best collaborate with Massachusetts companies and government, and hear the findings of new research about the size and character of the shared economic success of Israel and the Bay State.

1. Leveraging Israeli Innovation in Massachusetts: Results of New Research

• David Goodtree, Advisor, New England Israel Business Council

2. Case Studies: Successful Israeli Originated Companies Operating in MA

• Shimon Eckhouse, Chairman, Syneron, OrSense, CardioDex, NanoCyte, Tulip, Navotek, Rapid Medical

• Paul Valentine, President and Chief Executive Officer, Sleep HealthCenters

3. Today and Tomorrow in Massachusetts

• Ted Carr, Executive Director. Massachusetts Office of International Trade & Investment

• Robert Coughlin, President and CEO, Massachusetts Biotechnology Council

• Tom Sommer, President, Massachusetts Medical Device Industry Council

• Susan Windham-Bannister, Ph.D., President and CEO, Massachusetts Life Sciences Center

Day 2 - October 19, 2010
at Brandeis University Hassenfeld Conference Center, 415 South Street, Waltham, MA 02454

Presentations, Israeli Life Sciences Companies

Building Successful Life Science Companies in 2010 - Lessons from Experienced Entrepreneurs

Moderator: Alan Crane, General Partner, Polaris Venture Partners

• Bob Connelly, CEO, Pulmatrix

• Hezi Himelfarb, CEO, IceCure Medical

• Stan Lapidus, President and CEO, SynapDx; Founder of Cytyc, EXACT Sciences and Helicos BioSciences

• Amar Sawhney, President and CEO, Ocular Therapeutix; Director and Founder, AccessClosure